Cargando…
Thymic malignancies: next-generation sequencing as a tool to select patients for targeted therapies and immunotherapies?
The management of thymic malignancies is based on multidisciplinary discussion. Systemic agents may be administered as an exclusive treatment if local treatment is not achievable. Novel and innovative agents are used based on the results of next-generation sequencing that may report the activation o...
Autor principal: | Girard, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794339/ https://www.ncbi.nlm.nih.gov/pubmed/35118264 http://dx.doi.org/10.21037/med.2019.09.03 |
Ejemplares similares
-
Treatment options for stage IVA thymic malignancies
por: Girard, Nicolas
Publicado: (2019) -
Optimal management of thymic malignancies: current perspectives
por: Drevet, Gabrielle, et al.
Publicado: (2019) -
Narrative review of immunotherapy in thymic malignancies
por: Benitez, Jose Carlos, et al.
Publicado: (2021) -
Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display
por: Krohn, Steffen, et al.
Publicado: (2022) -
Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review
por: Agrafiotis, Apostolos C., et al.
Publicado: (2023)